Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 31

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 31
---
 form of a stock option in connection with their commencement of employment with us. Additional grants may occur periodically in order to specifically incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance.

Prior to our March 2022 initial public offering, we granted stock options pursuant to our Amended and Restated 2017 Equity Incentive Plan (the “2017 Plan”). All equity incentive awards granted since our initial public offering have been granted pursuant to our 2022 Equity Incentive Plan (the “2022 Plan”).

All stock options are granted with an exercise price per share that is no less than the fair market value of our common stock on the date of grant of such award. Our stock option awards granted to our named executive officers generally vest over a four-year period and may be subject to acceleration of vesting and exercisability under certain termination and change in control events, as described in more detail under the subsections below titled “Named Executive Officer Employment Arrangements” and “Potential Payments and Benefits upon Termination or Change in Control.” RSUs granted by the Company are subject to unique vesting schedules, and generally vest over a two to four year period.

<div align='center'>16</div>

The following table sets forth the options and RSUs granted to our NEOs in 2024:

| Name               |     | Grant Date |     | 2024 Option Award 
 (

# shares)        |     | 2024 RSU Award 
 (

# shares)     |
| Eric Easom         |     | 3/15/2024  |     | 198,000(1)        |     | 99,000(2)      |
| Josh Eizen         |     | 3/15/2024  |     | 60,000(1)         |     | 30,000(2)      |
|                    |     | 7/10/2024  |     |                   |     | 60,000(3)      |
|                    |     | 11/04/2024 |     | 63,000(4)         |     | 31,500(5)      |
| Lucy Day           |     | 3/15/2024  |     | 55,000(1)         |     | 27,500(2)      |
| Paul Eckburg, M.D. |     | 3/15/2024  |